Bristol-Myers Squibb Company (BMY) stock is expected to deviate a maximum of $13.45 from the average target price of $73.79 for the short term period. 14 Street Experts have initiated coverage on the stock with the most promising target being $100 and the most muted being $48.
The short interest in Bristol-Myers Squibb Company (BMY) has declined from 17,504,033 on June 15,2016 to 16,020,819 on June 30,2016. The change was measured at 1,483,214 shares or 8.5%. The leftover shorts were 1% of the floated shares. The days to cover are 2, given the average daily volume of 7,762,048 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.
Also, Equity Analysts at the Jefferies maintains the rating on Bristol-Myers Squibb Company (NYSE:BMY). The brokerage firm has issued a Hold rating on the shares. The Analysts at the ratings agency raises the price target from $76 per share to $78 per share. The rating by the firm was issued on June 14, 2016.
Bristol-Myers Squibb Company (NYSE:BMY): stock turned positive on Thursday. Though the stock opened at $76.79, the bulls momentum made the stock top out at $76.92 level for the day. The stock recorded a low of $76.29 and closed the trading day at $76.77, in the green by 0.25%. The total traded volume for the day was 4,352,625. The stock had closed at $76.58 in the previous days trading.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.